



Anatara Lifesciences announces leadership change

- **CEO resignation effective 26th June 2022**
- **Chair to assume interim executive role**

MELBOURNE, 5 May 2022: Anatara Lifesciences (ASX: ANR or “the Company”), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, today announced the resignation of its Chief Executive Officer, Mr. Steven Lydeamore. Mr. Lydeamore, who has been with the Company for three and a half years, will remain in the position until the last week of June to assist with an orderly transfer before pursuing other business interests.

Chair of Anatara, Dr. David Brookes said “On behalf of our Board, I would like to thank Steven for his leadership and significant contribution to the Company over the last three and a half years. During this time Anatara has faced major headwinds with the return of global rights to Detach® followed by the Covid-19 pandemic. With limited resources, the Anatara team developed new formulations for piglets and poultry, both of which have been successful in proof of concept challenge studies. With a changed strategic focus towards a human health emphasis, the Anatara team successfully completed GMP development of the novel GaRP technology. This GaRP technology is unique and believed to be the only complementary medicine with release of active components to two different locations in the gastrointestinal tract. Two products have so far been developed utilising this technology, both of which are presently undergoing human clinical studies in irritable bowel syndrome and psychological health respectively.”

Chief Executive Officer of Anatara, Mr. Steven Lydeamore, said “I am grateful for the opportunity given to me by the stakeholders of Anatara and would like to personally thank the Anatara Board for their support. I am proud of our achievements and am confident that upon successful completion of the human clinical studies, Anatara’s GaRP technology may be successfully commercialised and may provide breakthrough solutions sought by people with gastrointestinal disorders.”

Dr. David Brookes said “The Board will work closely with Steven to manage the transition by the end of the financial year. Upon completion of this transition, I will take the role of Executive Chair with appropriate support and the Board’s intention is not to immediately seek a replacement for the CEO role. With several important inflection points looming, notably the GaRP trial interim read out for dose selection expected in 3rd quarter of this calendar year, the Board is of the view that it is prudent to delay the recruitment process”.

Authorised by: The Board of Anatara Lifesciences Ltd.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatarata Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatarata.com	Dr. David Brookes Chair, Anatarata Lifesciences Ltd +61 (0) 411 712 579 dbrookes@anatarata.com

About Anatarata Lifesciences Ltd

Anatarata Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatarata is a life sciences company with expertise in developing products for human and animal health. Anatarata is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatarata Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

